CHEMOTHERAPY MAY. 1988

Similar documents

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL.42 S-1

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL. 34 S-2 CHEMOTH8RAPY 913

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY JUNE 1986

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY

988 CHEMOTHERAPY NOV. 1971



Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

Table1MIC of BAY o 9867 against standard strains

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent


2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1





Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


CHEMOTHERAPY


日本化学療法学会雑誌第59巻第5号





VOL. 43 NO. 4



CHEMOTHERAPY

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)



THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

VOL.39 S-3

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac





明海大学歯学雑誌　３７‐２／１．秦泉寺

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

東洋医学雑誌

Transcription:

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY Fig. 1 Chemical structure

CHEMOTHERAPY MAY. 1988

VOL.36 5-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

VOL.36 S-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

VOL.36 S-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY Table 3 Distribution of sex and weight Table 4 Clinical effect classified by duration of administration

CHEMOTHERAPY Table 5 Clinical efficacy classified by diagnosis and daily dose

VOL 36 S- I CHEMOTHERAPY Table 6 Clinical efficacy of CS-807 (physician's assessment) Table 7 Clinical efficacy of CS-807 (attending committee's assessment)

CHEMOTHERAPY MAY, 1988 Table 8 Clinical effect of CS-807 in cases treated with other antibiotics for 3 days or longer with poor result Table 9 Bacteriological efficacy of CS-807 classified by diagnosis

VOL.36 S-1 CHEMOTHERAPY (Monomicrobial) Table 10 Clinical effect of CS-807 classified by clinical isolates (Physician's assessment) Tablet 11 Clinical effect of CS-807 classified by clinical isolates (Physician's assessment) (Polymicrobial)

CHEMOTHERAPY MAY. 1988 (Monomicrobial) Table 12 Bacteriological efficacy of CS-807 classified by clinical isolates (1) (Polymicrobial) Table 13 Bacteriological efficacy of CS-807 classified by clinical isolates (2)

VOL.36 S-1 CHEMOTHERAPY Table 14 MICs of R-3763 against clinical isolates (106 cells/m1)

CHEMOTHERAPY MAY. 1988 Fig. 2 Susceptibility of S. aureus to R.3763 (46 strains 106 cells/ml) Fig. 3 Susceptibility of S. aureus to R-3763 (46 strains 108 cells/ml)

VOL.36 S-1 CHEMOTHERAPY Fig. 4 Susceptibility of S. epidermidis to R-3763 (17 strains 106 cells/ml) Fig. 5 Susceptibility of S. epidermidis to R-3763 (17 strains 108 cells/ml).

CHEMOTHERAPY 2) T. KOMAI, K. FUJIMOTO, M. SEKINE and H. MASUDA: CS-807, a New Orally Active C-ephalosporin. Absorption-excretion Studies in Experimental of the Twenty-Sixth Antimicrobial 1986, New Orleans. Animals., Program and Abstracts Interscience Conference on Agents and Chemotherapy p.205, 3) S. SUGAWARA, M. IWATA, M. TAJIMA, T. MAGARI- BUCHI, H. YANAGISAWA, H. NAKAO, J. KUMAZAWA and S. KUWAHARA: Res. Labs., Sankyo Co., Ltd., CS-807, a New Orally Active Cephalosporin. In vitro and in vivo Antibacterial Activities., Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy p.205, 1986, New Orleans.

CHEMOTHERAPY 647 CLINICAL APPLICATION OF CS-807, AN ORAL CEPHALOSPORIN ANTIBIOTIC, TO SKIN AND SOFT-TISSUE INFECTIONS ISSEI NAKAYAMA Third Department of Surgery, Nihon University School of Medicine, Tokyo EMIKO YAMAJI, HIROSHI KAWAMURA, HIROSHI KAWAGUCHI Microbiological Section, The Center of Health Science, Nihon University School of Medicine, Tokyo Yozo AKIEDA Department of Surgery, Akieda Hospital, Tokyo TETSUYA WATANABE Department of Surgery, Itabashi Chuo Sogo Hospital, Tokyo TOSHIAKI SUZUKI Department of Surgery, Kanamemachi Hospital, Tokyo KANJI ITOKAWA Department of Surgery, Seya Chuo Hospital KAZUE UENO, KUNITOMO WATANABE, TERUKO KANAZAWA Institute of Anaerobic Bacteriology, School of Medicine, Gifu University, Gifu Clinical study was made of a new oral cephalosporin antibiotic CS-807 on skin and soft tissue infections. Subject diseases were 144 cases of suppurative atheroma, felon, furuncle, carbuncle, subcutaneous abscess, phlegmon, periproctal abscess, lymphadenitis, lymphangitis, wound infection, paronychia, subareolar abscess, suppurative mastitis, suppurative hydradenitis, omphalitis, suppurative folliculitis, etc. Clinical effects judged by the physicians in charge were : excellent - 25 cases ; good - 96 cases ; fair - 17 cases ; and poor - 6 cases out of 144 cases, efficacy rate being 84.0%. On the other hand, clinical effects according to the unified judgement standards were : excellent - 83 cases ; good - 46 cases ; fair - 7 cases ; and poor - 8 cases, efficacy rate being 89.6%. Clinical effects by dose were found as : efficacy rate 80.6% in 200 mg daily dose group and 85.9% in 400 mg group, and stochastically 400 mg group showed superior clinical effect, compared with 200 mg group. In bacteriological study, rate of elimination was seen as 86.9% in 61 cases of single infection and 93% in 57 cases of mixed infection. Clinical effect of this drug on the cases in whom preliminarily-administered drug was ineffective showed results more than good in 12 cases out of 15, efficacy rate being 80%. Regarding adverse effect, there was no case who showed subjective or objective symptom among 144 cases. Investigation of abnormal clinical test value was possible in 1 case but no particular abnormality was observed. As a result of investigating MIC in 179 strains of 36 species, 144 strains (80.4%) out of 179 showed a distribution at a level lower than 3.13 pg/ ml of this drug.

2026 © docsplayer.net プライバシー | 利用規約 | フィードバック